VEDBAEK, Denmark, May 23, 2011 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ) today announced that results from a diagnostic program on the potential of using circulating microRNAs in serum as companion diagnostic biomarkers has been selected for presentation at the 2011 ASCO meeting to be held June 3-6 in Chicago.
The title of the work is: "The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P) carboplatin (C)". Abstract No: 10548 Citation: J Clin Oncol 29: 2011 (suppl; abstr 10548).
"The selection for presentation at the ASCO is a reflection of the great progress being made in demonstrating the utility of miRNAs present in blood derived serum or plasma as biomarkers.", says Adam Baker, VP of Diagnostics at Exiqon.
For more information, please visit the 2011 ASCO Annual Meeting home page at:
Abstract page:
Please see the full press release in the attached PDF-file.
Attachments: